GlassScriptPhysician profile
Christopher Alan Stansbury
NPI 1376569814
$2,154.33
in general payments reported to CMS, 2019-2025
10 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.34 · 2021: $78.78 · 2022: $87.21 · 2023: $370 · 2024: $1,313 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $973.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,023.25 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Abbvie INC. | $581.57 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $326.30 | 2021-2025 | Simbrinza, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $109.89 | 2023-2025 | Infuse, Biotrue One Day, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $26.23 | 2024 | Tecnis Iol |
| Harrow Eye, LLC | $23.54 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $19.34 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.38 | 2022 | |
| Allergan, INC. | $15.34 | 2020 | |
| Lkc Technologies, INC. | $12.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stansbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.